Black Myth: Wukong won the best action game of the year by TGA.The three major stock indexes all fell more than 1%, the Shanghai Composite Index fell 1%, the Shenzhen Composite Index fell 1.28%, the Growth Enterprise Market Index fell 1.49%, and more than 4,100 stocks in the whole market fell.In the exchange market, the national debt rose the most, with "National Debt 2404" rising more than 4%, "National Debt 23", "Special Country 24 03" and "Special Country 24 01" rising nearly 1%.
Zheshang Securities: It does not rule out the possibility of lowering the RRR and cutting interest rates at the same time before the end of the year. Zheshang Securities research report said that this central economic work conference went further on the basis of the previous Politburo meeting, and clearly put forward "timely RRR reduction and interest rate reduction". Combined with the central bank's statement on the RRR reduction space in late September, it is expected that there will be a 50-basis-point RRR reduction before the end of the year, which will greatly promote interest rate reduction in the first quarter of next year, and even does not rule out the possibility of simultaneous RRR reduction and interest rate reduction before the end of the year. We are optimistic that the equity market and the bond market will step out of the double bull market in the process of gradual policy development.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)Chief Cabinet Secretary of Japan: Short-term data show that enterprises have a strong willingness to invest.
The Hang Seng Index and Hang Seng Technology Index both fell more than 1%.The central bank's open market today launched a 7-day reverse repurchase operation of 205.1 billion yuan, and the operating interest rate was flat at 1.50%. Today, 190.9 billion yuan of 7-day reverse repurchase expired, and the net investment on that day was 14.2 billion yuan.Bestak: Actively deploy the C-end smart product business. At present, it has not cooperated with Bean Bag AI. Bestak said at the performance briefing on December 12 that on the one hand, the company actively deployed the C-end smart product business, exerted its own brand, promoted business expansion with category innovation, and continuously enhanced the strategic value of the new development pattern. On the other hand, the company invested in the layout of cross-border e-commerce companies, and joined hands with them to promote the series of inflator products to the sea, strengthen the cross-border e-commerce coordination strategy, and vigorously explore the potential market. In addition, the company said that the company has not cooperated with Bean Bag AI at present.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14